Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 164163, 10 pages
http://dx.doi.org/10.1155/2008/164163
Review Article

PPAR- in Vascular Pathophysiology

Laboratory of Vascular Molecular Biology and Bioengineering, Institute of Cardiovascular Science and Diabetes Center, Peking University Health Science Center, Beijing 100191, China

Received 25 July 2008; Accepted 27 October 2008

Academic Editor: Francine M. Gregoire

Copyright © 2008 Nanping Wang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
  2. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar
  3. Y. Barak, D. Liao, W. He et al., “Effects of peroxisome proliferator-activated receptor d on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 303–308, 2002. View at Publisher · View at Google Scholar
  4. J. M. Peters, S. S. T. Lee, W. Li et al., “Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor ß(d),” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5119–5128, 2000. View at Publisher · View at Google Scholar
  5. N. S. Tan, L. Michalik, N. Di-Poï, B. Desvergne, and W. Wahli, “Critical roles of the nuclear receptor PPARβ (peroxisome-proliferator-activated receptor β) in skin wound healing,” Biochemical Society Transactions, vol. 32, no. 1, pp. 97–102, 2004. View at Publisher · View at Google Scholar
  6. N. S. Tan, L. Michalik, N. Noy et al., “Critical roles of PPARß/d in keratinocyte response to inflammation,” Genes & Development, vol. 15, no. 24, pp. 3263–3277, 2001. View at Publisher · View at Google Scholar
  7. L. Michalik, B. Desvergne, N. S. Tan et al., “Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)a and PPARß mutant mice,” Journal of Cell Biology, vol. 154, no. 4, pp. 799–814, 2001. View at Publisher · View at Google Scholar
  8. C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, “Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors,” Cell, vol. 68, no. 5, pp. 879–887, 1992. View at Publisher · View at Google Scholar
  9. A. Schmidt, R. L. Vogel, K. M. Witherup et al., “Identification of fatty acid methyl ester as naturally occurring transcriptional regulators of the members of the peroxisome proliferator-activated receptor family,” Lipids, vol. 31, no. 11, pp. 1115–1124, 1996. View at Publisher · View at Google Scholar
  10. T. Yoshikawa, Z. Brkanac, B. R. Dupont, G.-Q. Xing, R. J. Leach, and S. D. Detera-Wadleigh, “Assignment of the human nuclear hormone receptor, NUC1 (PPARD), to chromosome 6p21.1-p21.2,” Genomics, vol. 35, no. 3, pp. 637–638, 1996. View at Publisher · View at Google Scholar
  11. S. A. Fyffe, M. S. Alphey, L. Buetow et al., “Recombinant human PPAR-ß/d ligand-binding domain is locked in an activated conformation by endogenous fatty acids,” Journal of Molecular Biology, vol. 356, no. 4, pp. 1005–1013, 2006. View at Publisher · View at Google Scholar
  12. H. E. Xu, M. H. Lambert, V. G. Montana et al., “Molecular recognition of fatty acids by peroxisome proliferator-activated receptors,” Molecular Cell, vol. 3, no. 3, pp. 397–403, 1999. View at Publisher · View at Google Scholar
  13. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at Publisher · View at Google Scholar
  14. K. Yu, W. Bayona, C. B. Kallen et al., “Differential activation of peroxisome proliferator-activated receptors by eicosanoids,” The Journal of Biological Chemistry, vol. 270, no. 41, pp. 23975–23983, 1995. View at Publisher · View at Google Scholar
  15. G. Krey, O. Braissant, F. L'Horset et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay,” Molecular Endocrinology, vol. 11, no. 6, pp. 779–791, 1997. View at Publisher · View at Google Scholar
  16. R. A. Gupta, J. Tan, W. F. Krause et al., “Prostacyclin-mediated activation of peroxisome proliferator-activated receptor d in colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 24, pp. 13275–13280, 2000. View at Publisher · View at Google Scholar
  17. A. Chawla, C.-H. Lee, Y. Barak et al., “PPARd is a very low-density lipoprotein sensor in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 1268–1273, 2003. View at Publisher · View at Google Scholar
  18. N. Shaw, M. Elholm, and N. Noy, “Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor β/δ,” The Journal of Biological Chemistry, vol. 278, no. 43, pp. 41589–41592, 2003. View at Publisher · View at Google Scholar
  19. M. L. Sznaidman, C. D. Haffner, P. R. Maloney et al., “Novel selective small molecule agonists for peroxisome proliferator-activated receptor d (PPARd)—synthesis and biological activity,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 9, pp. 1517–1521, 2003. View at Publisher · View at Google Scholar
  20. C. Santini, G. D. Berger, W. Han et al., “Phenylacetic acid derivatives as hPPAR agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 7, pp. 1277–1280, 2003. View at Publisher · View at Google Scholar
  21. B. G. Shearer, D. J. Steger, J. M. Way et al., “Identification and characterization of a selective peroxisome proliferator-activated receptor ß/d (NR1C2) antagonist,” Molecular Endocrinology, vol. 22, no. 2, pp. 523–529, 2008. View at Publisher · View at Google Scholar
  22. L. Piqueras, A. R. Reynolds, K. M. Hodivala-Dilke et al., “Activation of PPARß/d induces endothelial cell proliferation and angiogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 63–69, 2007. View at Publisher · View at Google Scholar
  23. S. Dimmeler, J. Haendeler, and A. M. Zeiher, “Regulation of endothelial cell apoptosis in atherothrombosis,” Current Opinion in Lipidology, vol. 13, no. 5, pp. 531–536, 2002. View at Publisher · View at Google Scholar
  24. N. Wang and M. B. Stemerman, “Ref-1 and transcriptional control of endothelial apoptosis,” Circulation Research, vol. 88, no. 12, pp. 1223–1225, 2001. View at Publisher · View at Google Scholar
  25. E. Letavernier, J. Perez, E. Joye et al., “Peroxisome proliferator-activated receptor ß/d exerts a strong protection from ischemic acute renal failure,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2395–2402, 2005. View at Publisher · View at Google Scholar
  26. J.-Y. Liou, S. Lee, D. Ghelani, N. Matijevic-Aleksic, and K. K. Wu, “Protection of endothelial survival by peroxisome proliferator-activated receptor-δ mediated 14-3-3 upregulation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 7, pp. 1481–1487, 2006. View at Publisher · View at Google Scholar
  27. L. Brunelli, K. A. Cieslik, J. L. Alcorn, M. Vatta, and A. Baldini, “Peroxisome proliferator-activated receptor-δ upregulates 14-3-3ε in human endothelial cells via CCAAT/enhancer binding protein-β,” Circulation Research, vol. 100, no. 5, pp. e59–e71, 2007. View at Publisher · View at Google Scholar
  28. T. M. Carlos and J. M. Harlan, “Leukocyte-endothelial adhesion molecules,” Blood, vol. 84, no. 7, pp. 2068–2101, 1994. View at Google Scholar
  29. N. Marx, G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky, “PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells,” Circulation, vol. 99, no. 24, pp. 3125–3131, 1999. View at Google Scholar
  30. K. Goya, S. Sumitani, X. Xu et al., “Peroxisome proliferator-activated receptor a agonists increase nitric oxide synthase expression in vascular endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 4, pp. 658–663, 2004. View at Publisher · View at Google Scholar
  31. N. Wang, L. Verna, N.-G. Chen et al., “Constitutive activation of peroxisome proliferator-activated receptor-? suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells,” The Journal of Biological Chemistry, vol. 277, no. 37, pp. 34176–34181, 2002. View at Publisher · View at Google Scholar
  32. V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. H. Yeh, “Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators,” Circulation, vol. 101, no. 3, pp. 235–238, 2000. View at Google Scholar
  33. H. Lee, W. Shi, P. Tontonoz et al., “Role for peroxisome proliferator-activated receptor a in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 interleukin-8 by endothelial cells,” Circulation Research, vol. 87, no. 6, pp. 516–521, 2000. View at Google Scholar
  34. N. Marx, T. Bourcier, G. K. Sukhova, P. Libby, and J. Plutzky, “PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 3, pp. 546–551, 1999. View at Google Scholar
  35. J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003. View at Publisher · View at Google Scholar
  36. A. C. Li, C. J. Binder, A. Gutierrez et al., “Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARa, ß/d, and ?,” Journal of Clinical Investigation, vol. 114, no. 11, pp. 1564–1576, 2004. View at Publisher · View at Google Scholar
  37. T. L. Graham, C. Mookherjee, K. E. Suckling, C. N. A. Palmer, and L. Patel, “The PPARδ agonist GW0742X reduces atherosclerosis in LDLR/ mice,” Atherosclerosis, vol. 181, no. 1, pp. 29–37, 2005. View at Publisher · View at Google Scholar
  38. Y. Rival, N. Benéteau, T. Taillandier et al., “PPARa and PPARd activators inhibit cytokine-induced nuclear translocation of NF-?B and expression of VCAM-1 in EAhy926 endothelial cells,” European Journal of Pharmacology, vol. 435, no. 2-3, pp. 143–151, 2002. View at Publisher · View at Google Scholar
  39. Y. Fan, Y. Wang, Z. Tang et al., “Suppression of pro-inflammatory adhesion molecules by PPAR-d in human vascular endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 2, pp. 315–321, 2008. View at Publisher · View at Google Scholar
  40. M. Ghosh, H. Wang, Y. Ai et al., “COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARd activation,” The Journal of Experimental Medicine, vol. 204, no. 9, pp. 2053–2061, 2007. View at Publisher · View at Google Scholar
  41. R. S. Bresalier, R. S. Sandler, H. Quan et al., “Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial,” The New England Journal of Medicine, vol. 352, no. 11, pp. 1092–1102, 2005. View at Publisher · View at Google Scholar
  42. J. Folkman, “Angiogenesis,” Annual Review of Medicine, vol. 57, pp. 1–18, 2006. View at Publisher · View at Google Scholar
  43. P. Fraisl, M. Baes, and P. Carmeliet, “Hungry for blood vessels: linking metabolism and angiogenesis,” Developmental cell, vol. 14, no. 3, pp. 313–314, 2008. View at Publisher · View at Google Scholar
  44. P. Carmeliet and M. Baes, “Metabolism and therapeutic angiogenesis,” The New England Journal of Medicine, vol. 358, no. 23, pp. 2511–2512, 2008. View at Publisher · View at Google Scholar
  45. R. L. Stephen, M. C. U. Gustafsson, M. Jarvis et al., “Activation of peroxisome proliferator-activated receptor d stimulates the proliferation of human breast and prostate cancer cell lines,” Cancer Research, vol. 64, no. 9, pp. 3162–3170, 2004. View at Publisher · View at Google Scholar
  46. C. Gaudel, C. Schwartz, C. Giordano, N. A. Abumrad, and P. A. Grimaldi, “Pharmacological activation of PPARβ promotes rapid and calcineur-independent fiber remodeling and angiogenesis in mouse skeletal muscle,” American Journal of Physiology, vol. 295, no. 2, pp. E297–E304, 2008. View at Publisher · View at Google Scholar
  47. A. Luttun, G. Carmeliet, and P. Carmeliet, “Vascular progenitors: from biology to treatment,” Trends in Cardiovascular Medicine, vol. 12, no. 2, pp. 88–96, 2002. View at Publisher · View at Google Scholar
  48. T. Asahara, T. Murohara, A. Sullivan et al., “Isolation of putative progenitor endothelial cells for angiogenesis,” Science, vol. 275, no. 5302, pp. 964–967, 1997. View at Publisher · View at Google Scholar
  49. T. He, T. Lu, L. V. d'Uscio, C. F. Lam, H. C. Lee, and Z. S. Katusic, “Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells,” Circulation Research, vol. 103, no. 1, pp. 80–88, 2008. View at Publisher · View at Google Scholar
  50. A. Abdollahi, C. Schwager, J. Kleeff et al., “Transcriptional network governing the angiogenic switch in human pancreatic cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 31, pp. 12890–12895, 2007. View at Publisher · View at Google Scholar
  51. S. Müller-Brüsselbach, M. Kömhoff, M. Rieck et al., “Deregulation of tumor angiogenesis and blockade of tumor growth in PPARß-deficient mice,” The EMBO Journal, vol. 26, no. 15, pp. 3686–3698, 2007. View at Publisher · View at Google Scholar
  52. J. Zhang, M. Fu, X. Zhu et al., “Peroxisome proliferator-activated receptor d is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 277, no. 13, pp. 11505–11512, 2002. View at Publisher · View at Google Scholar
  53. H.-J. Lim, S. Lee, J.-H. Park et al., “PPARd agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle,” Atherosclerosis. In press. View at Publisher · View at Google Scholar
  54. H. J. Kim, S. A. Ham, S. U. Kim et al., “Transforming growth factor-ß1 is a molecular target for the peroxisome proliferator-activated receptor d,” Circulation Research, vol. 102, no. 2, pp. 193–200, 2008. View at Publisher · View at Google Scholar
  55. Y. Numaguchi, K. Okumura, M. Harada et al., “Catheter-based prostacyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries,” Cardiovascular Research, vol. 61, no. 1, pp. 177–185, 2004. View at Publisher · View at Google Scholar
  56. H. Imai, Y. Numaguchi, M. Ishii et al., “Prostacyclin synthase gene transfer inhibits neointimal formation by suppressing PPARd expression,” Atherosclerosis, vol. 195, no. 2, pp. 322–332, 2007. View at Publisher · View at Google Scholar
  57. M. Yamada, Y. Numaguchi, K. Okumura et al., “Prostacyclin synthase gene transfer modulates cyclooxygenase-2-derived prostanoid synthesis and inhibits neointimal formation in rat balloon-injured arteries,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 2, pp. 256–262, 2002. View at Publisher · View at Google Scholar
  58. W. R. Oliver Jr., J. L. Shenk, M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor d agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 9, pp. 5306–5311, 2001. View at Publisher · View at Google Scholar
  59. H. Vosper, L. Patel, T. L. Graham et al., “The peroxisome proliferator-activated receptor d promotes lipid accumulation in human macrophages,” The Journal of Biological Chemistry, vol. 276, no. 47, pp. 44258–44265, 2001. View at Publisher · View at Google Scholar
  60. C.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at Publisher · View at Google Scholar
  61. G. D. Barish, A. R. Atkins, M. Downes et al., “PPARd regulates multiple proinflammatory pathways to suppress atherosclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 11, pp. 4271–4276, 2008. View at Publisher · View at Google Scholar
  62. A. Trifilieff, A. Bench, M. Hanley, D. Bayley, E. Campbell, and P. Whittaker, “PPAR-α and -γ but not -δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-κB-independent effect,” British Journal of Pharmacology, vol. 139, no. 1, pp. 163–171, 2003. View at Publisher · View at Google Scholar
  63. Y. Takata, J. Liu, F. Yin et al., “PPARd-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 11, pp. 4277–4282, 2008. View at Publisher · View at Google Scholar
  64. Y.-X. Wang, C.-H. Lee, S. Tiep et al., “Peroxisome-proliferator-activated receptor d activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. View at Publisher · View at Google Scholar
  65. T. Tanaka, J. Yamamoto, S. Iwasaki et al., “Activation of peroxisome proliferator-activated receptor d induces fatty acid ß-oxidation in skeletal muscle and attenuates metabolic syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15924–15929, 2003. View at Publisher · View at Google Scholar
  66. K. C. Choi, S. Y. Lee, H. J. Yoo et al., “Effect of PPAR-d agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 357, no. 1, pp. 62–67, 2007. View at Publisher · View at Google Scholar
  67. J. N. van der Veen, J. K. Kruit, R. Havinga et al., “Reduced cholesterol absorption upon PPARd activation coincides with decreased intestinal expression of NPC1L1,” Journal of Lipid Research, vol. 46, no. 3, pp. 526–534, 2005. View at Publisher · View at Google Scholar
  68. M. D. Leibowitz, C. Fiévet, N. Hennuyer et al., “Activation of PPARd alters lipid metabolism in db/db mice,” FEBS Letters, vol. 473, no. 3, pp. 333–336, 2000. View at Publisher · View at Google Scholar
  69. D. L. Sprecher, C. Massien, G. Pearce et al., “Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor d agonist,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 359–365, 2007. View at Publisher · View at Google Scholar
  70. D. K. Krämer, L. Al-Khalili, S. Perrini et al., “Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor d,” Diabetes, vol. 54, no. 4, pp. 1157–1163, 2005. View at Publisher · View at Google Scholar
  71. D. K. Krämer, L. Al-Khalili, B. Guigas, Y. Leng, P.M. Garcia-Roves, and A. Krook, “Role of AMP kinase and PPARδ in the regulation of lipid and glucose metabolism in human skeletal muscle,” The Journal of Biological Chemistry, vol. 282, no. 27, pp. 19313–19320, 2007. View at Publisher · View at Google Scholar
  72. S. Terada, S. Wicke, J. O. Holloszy, and D.-H. Han, “PPARδ activator GW-501516 has no acute effect on glucose transport in skeletal muscle,” American Journal of Physiology, vol. 290, no. 4, pp. E607–E611, 2006. View at Publisher · View at Google Scholar
  73. C.-H. Lee, P. Olson, A. Hevener et al., “PPARd regulates glucose metabolism and insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3444–3449, 2006. View at Publisher · View at Google Scholar
  74. X. Qin, X. Xie, Y. Fan et al., “Peroxisome proliferator-activated receptor-d induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice,” Hepatology, vol. 48, no. 2, pp. 432–441, 2008. View at Publisher · View at Google Scholar
  75. L. J. Engelking, H. Kuriyama, R. E. Hammer et al., “Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis,” The Journal of Clinical Investigation, vol. 113, no. 8, pp. 1168–1175, 2004. View at Publisher · View at Google Scholar
  76. D. Yabe, R. Komuro, G. Liang, J. L. Goldstein, and M. S. Brown, “Liver-specific mRNA for insig-2 down-regulated by insulin: implications for fatty acid synthesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 6, pp. 3155–3160, 2003. View at Publisher · View at Google Scholar
  77. U. Risérus, D. Sprecher, T. Johnson et al., “Activation of peroxisome proliferator-activated receptor (PPAR)d promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men,” Diabetes, vol. 57, no. 2, pp. 332–339, 2008. View at Publisher · View at Google Scholar
  78. J. Skogsberg, K. Kannisto, T. N. Cassel, A. Hamsten, P. Eriksson, and E. Ehrenborg, “Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 4, pp. 637–643, 2003. View at Publisher · View at Google Scholar
  79. J. Skogsberg, A. D. McMahon, F. Karpe, A. Hamsten, C. J. Packard, and E. Ehrenborg, “Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men,” Journal of Internal Medicine, vol. 254, no. 6, pp. 597–604, 2003. View at Publisher · View at Google Scholar
  80. J. Aberle, I. Hopfer, F. U. Beil, and U. Seedorf, “Association of the T+294C polymorphism in PPAR δ with low HDL cholesterol and coronary heart disease risk in women,” International Journal of Medical Sciences, vol. 3, no. 3, pp. 108–111, 2006. View at Google Scholar
  81. J. Aberle, I. Hopfer, F. U. Beil, and U. Seedorf, “Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V,” International Journal of Obesity, vol. 30, no. 12, pp. 1709–1713, 2006. View at Publisher · View at Google Scholar
  82. S. Chen, N. Tsybouleva, C. M. Ballantyne, A. M. Gotto Jr., and A. J. Marian, “Effects of PPARα, γ and δ haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study,” Pharmacogenetics, vol. 14, no. 1, pp. 61–71, 2004. View at Publisher · View at Google Scholar
  83. M. Vänttinen, P. Nuutila, T. Kuulasmaa et al., “Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor d gene are associated with skeletal muscle glucose uptake,” Diabetes, vol. 54, no. 12, pp. 3587–3591, 2005. View at Publisher · View at Google Scholar
  84. H. D. Shin, B. L. Park, L. H. Kim et al., “Genetic polymorphisms in peroxisome proliferator-activated receptor d associated with obesity,” Diabetes, vol. 53, no. 3, pp. 847–851, 2004. View at Publisher · View at Google Scholar
  85. J. Robitaille, D. Gaudet, L. Pérusse, and M.-C. Vohl, “Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians,” International Journal of Obesity, vol. 31, no. 3, pp. 411–417, 2007. View at Publisher · View at Google Scholar
  86. V. A. Narkar, M. Downes, R. T. Yu et al., “AMPK and PPARd agonists are exercise mimetics,” Cell, vol. 134, no. 3, pp. 405–415, 2008. View at Publisher · View at Google Scholar
  87. R. A. Gupta, D. Wang, S. Katkuri, H. Wang, S. K. Dey, and R. N. DuBois, “Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth,” Nature Medicine, vol. 10, no. 3, pp. 245–247, 2004. View at Publisher · View at Google Scholar
  88. D. Wang, H. Wang, Y. Guo et al., “Crosstalk between peroxisome proliferator-activated receptor d and VEGF stimulates cancer progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 50, pp. 19069–19074, 2006. View at Publisher · View at Google Scholar